Trials / Completed
CompletedNCT00382733
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Oral Topotecan, Utilization for a Metronomic Dosing Schedule to Treat Recurrent or Persistent Solid Tumors
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Accelerated Community Oncology Research Network · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effectiveness of oral topotecan and how well the chemotherapy is tolerated (any side effects) when it is given in different dose levels. The study will also collect information on how the medication is being broken down and absorbed in the body and how quality of life is affected during treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Oral Topotecan | Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day. |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2011-03-01
- Completion
- 2011-03-01
- First posted
- 2006-09-29
- Last updated
- 2013-07-22
- Results posted
- 2013-07-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00382733. Inclusion in this directory is not an endorsement.